Olivier Terrier
  • E-mail :[email]
  • Phone : 0478771037
  • Location : Lyon, France
Last update 2019-10-28 13:34:18.818

Olivier Terrier CR1 CNRS, HDR, PhD in Virology/ Influenza and other respiratory viruses

Course and current status



Current position : Researcher, (CR1 CNRS, HDR), 

Olivier Terrier was appointed in 2015 as Associate Professor/permanent researcher (CR1 CNRS) in the VirPath Team (Pr Bruno Lina/Dr Manuela Rosa-Calatrava, https://www.virpath.com), which is part of the international Center for infectiology Research (CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon & Université CLaude Bernard Lyon 1, http://ciri.inserm.fr), based in Lyon, France.

During his PhD and postdoctoral works he acquired a good  expertise in the field of respiratory viruses (Families Paramyxoviridae and Orthomyxoviridae). During his first postdoctoral position (2009-2011, University of Dundee, Prof Sir David Lane’s group, Jean-Christophe Bourdon’s team) he initiated a new research thematic dedicated to the study of the functional interplay between influenza viruses and p53. Notably, he demonstrated for the first time the regulatory role of p53 isoforms in the context of a viral infection (Terrier et al. J Virol 2012). He also advantageously used different “omics-based” approaches in his projects. In this context, he notably published one of the first characterization of the influenza microRNAome in human lung epithelial cells (Terrier et al. J Gen Virol 2013).

Olivier Terrier published more than 34 manuscripts in internationally peer-reviewed journals (h-index= 14) and holds 10international patents. Olivier Terrier is currently member of the advisory board of the Influenza Research Database (www.fludb.org, NIH/J Craig Venter Institute). 

He regularly reviews manuscripts for international journals and program grants applications and he is currently Academic Editor for Scientific Reports and Review Editor for Frontiers in Microbiology.

Olivier Terrier is associate co-founder of Signia Therapeutics (https://signiatherapeutics.com), SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses.

Previous positions

2012-2015: Postdoctoral position. VirPath lab, Lyon , France (Dr Manuel Rosa-Calatrava). Study of the functional interplay between influenza viruses and the p53 pathway. Transcriptome -based identification and repurposing of antiviral molecules.

2010-2012: Associate postdoctoral researcher. Department of Surgery and Molecular Oncology, Dundee, UK (Prof Sir David P Lane and Dr Jean-Christophe Bourdon) in collaboration with VirPath lab EA4610, Lyon, France (Dr Manuel Rosa-Calatrava). Study of the interplay between influenza viruses and the p53 pathway.

2009-2010 : Postdoctoral position. FRE CNRS-UCBL 3011, Lyon, France (Prof. Bruno Lina). Influenza and parainfluenza envelope glycoproteins. 

2005-2009: Doctoral position. FRE CNRS-UCBL 3011, Lyon, France (Prof. Bruno Lina). Parainfluenza virus envelope glycoproteins: structure versus function study and development of diagnostic and therapeutic applications. 

2004-2005: Master studentFRE CNRS-UCBL 3011 and National reference center for Influenza (WHO collaborating center for Influenza), Lyon, France (Prof. Bruno Lina). Characterization of naturally occurring human parainfluenza type 2 virus (hPIV-2) variants. 

Nov. 2003-May 2004: Master student. Laboratoire de Microbiologie et génétique UMR 5122, Lyon, France (Prof. Raymond Portalier). Study of the gene expression in oligopeptide transport in Lactococcus lactis.

Scientific summary

Main ongoing projects

  • Transcriptional profiling of co-infections between respiratory viruses and bacteria in a reconstituted human respiratory epithelium model derived from healthy donors versus cystic fibrosis patients. (Funding Vaincre La Mucoviscidose)
  • COEPI - Study of Influenza/S pneumoniae co-infections in the context of cystic fibrosis (Funding FINOVI foundation, Association Vaincre La Mucoviscidose/Gregory Lemarchal)
  • FluGuard - Study of the interplay between influenza viruses and the p53 pathway.
  • FluNext/Respiromix - Identification of small molecules of interest in the field of respiratory viruses based on their transcriptional signatures of infection.
Image d’exemple